
Managing epilepsy is an increasingly expensive process in the United States, with prices of brand-name anti-seizure drugs nearly quadrupling over eight years, a new study finds. From 2010 to 2018, the cost of brand-named epilepsy drugs, including meds like Vimpat (lacosamide), rose 277% overall, researchers found. Over the same period, the cost of generic drugs… read on > read on >